KCAS has a diverse staff of 70 employees with an average tenure of 12 years. Many of our researchers are recognized as leading experts in their field.
John Bucksath, MBA
Mr. Bucksath joined ABC Laboratories as an analytical chemist in 1989. He was responsible for the successful start-up, growth and leadership of the company’s pharmaceutical CGMP Analytical Services group in the mid-1990s. John was promoted to VP of company operations in 2003 where he managed all operations of the organization’s pharmaceutical and agri-chemical business and was responsible for the company’s P/L. John was promoted to Sr. Vice President of Operations in 2005 and in 2007 initiated the Company’s program management function and Quality Management metric program. In 2008, John was named Senior Vice President and General Manager of the company’s Pharmaceutical Division where he was responsible for all aspects of the operations including business development. John developed and initiated the company’s intro into large molecule product development services. In September 2012, John was selected as President and CEO/Board member of ABC and Morse Laboratories. Under John’s leadership the Company grew at a CAGR of > 15% annually and in 2015, ABC Laboratories was successfully sold to the Evans Analytical Group (EAG).
John joined Kansas City Analytical Services (KCAS) as CEO/Board member in 2016. John serves on the Missouri Biotechnology Association’s Board of Directors as Treasurer and is a member of the University of Missouri’s Research and Development Advisory Board and is a member of the University of Missouri’s Venture Mentorship team focused on early startup life science companies. John has also served as an observing Board Member for two early-mid stage biotechnology companies.
John’s undergraduate education in Biology and Chemistry was obtained from Central Methodist University and a Masters of Business Administration from the Olin Business School – Washington University in St. Louis.
Michael Lanman, BS
Michael Lanman is Vice President of Operations at KCAS. Since joining the company in 1982, Michael has worked in and managed essentially every department within the company’s operations. A major emphasis in his business philosophy is focusing on customer communications and service. His responsibilities include overseeing day-to-day operations, managing budgets and contracts, IT support and ensuring the facilities are running smoothly. Michael leverages his extensive bioanalytical operational experience to ensure customer satisfaction and on-time projects. Michael holds a BA in Education from Bethany College in Lindsborg, KS.
Chris Frankovic, BS
Chris Frankovic is the Senior Director of Business Development & Marketing at KCAS. She has extensive experience in pharmaceutical research, including previous roles in operations and sales for Phase I, Clinical Pharmacology and Bioanalytical services. Chris clearly understands client expectations and strives to meet their objectives. Before joining the company, she held various positions in Phase I and Clinical Pharmacology at a large contract research organization. Chris received her BS in Microbiology from Kansas State University.
Justin Poley, BS
Justin Poley is a Director of Business Development at KCAS. Justin joined the company in 2015 and brought with him more than 20 years of experience in the biopharmaceutical industry and a diverse set of skills and knowledge. Justin has extensive experience in manufacturing, quality control and validation in addition to drug discovery technologies and development of genetic and cellular therapies. Prior to joining KCAS, Justin worked for Apollon, Cephalon, Puresyn, Aldevron, and Frontage. He spent twelve years in operations and business development for CMOs and CROs that specialized in gene therapy and biologics. He founded and operated a DNA purification company, Advanced Plasmids, which he sold to Aldevron in 2008. Most recently, he served as a principal consultant for NGT Consulting LLC, where he created and managed an annual cancer vaccines and gene therapy meeting. This meeting brought together important leaders to present and discuss the latest approaches and technologies used to develop promising anti-cancer therapeutics.
Gene Ray, PhD
Gene Ray, PhD, is a Senior Scientific Advisor, his role is to serve as scientific and technical advisor for both clients and internal teams for development, validation, and application of bioanalytical methods for small molecule therapeutics and alkaline hematin endpoint marker studies. Since joining the company in 1990, he has gained expertise is in a full range of bioanalytical techniques, including LC-MS/MS, GC/MS/MS, ELISA, RIA, protein binding and mass balance investigations. Gene has experience developing novel methods and acting as a Principal Bioanalytical Investigator for a vast number of client programs; analyzing hundreds of pharmaceutical compounds in blood, urine and various tissues. He previously served at Midwest Research Institute as the Assistant Director for numerous analytical chemistry programs for the National Cancer Institute.
Dominic Warrino, PhD
Dominic Warrino, PhD, is aSenior Scientific Advisor, his role is to serve as scientific and technical advisor for both clients and internal teams for development, validation, and application of bioanalytical, immunogenicity, and biomarker methods for large molecule therapeutics. Dominic joined the company in 2013, and brought with him expertise in a full range of bioanalytical techniques including ECL, ELISA, RIA, Flow Cytometry, ELISpot, cell based assays and Luminex. He has 20 years of experience developing and validating immunological assays for biotechnology and pharmaceutical companies. He most recently spent several years in the Biopharma Services department at Viracor-IBT (formally IBT), and previously also worked for Cytogen (formally Cellcor), Eligix, and Streck Laboratories developing novel compounds for treatment of various cancers. Dominic has worked on over 100 large molecule compounds developing and validating PK, PD, ADA, and Biomarker assays in support of pre-clinical to phase IV testing.
Yansheng Liu, PhD
Dr. Yansheng Liu is a Senior Director with KCAS, managing the Bioanalytical Research and Development team and the LC-MS/MS laboratory. He joined KCAS in 1997 after completion of his post-doctoral research in analytical chemistry at Indiana University. He has developed and validated hundreds of bioanalytical methods with his team using LC-MS/MS combined with on-line and off-line sample cleanup techniques. He diligently monitors the performance of each validated method to ensure quality performance over time. Dr. Lui excels at troubleshooting instrument-method, and operation-related problems to ensure quality and timeline management. He continuously demonstrates his dedication to clients’ bioanalytical needs in drug discovery and development activities and uses his strength in solving challenging bioanalytical problems to meet regulatory requirements. He has also authored over 40 publications and presentations.
Abu Siddiqui, PhD
Dr. Abu Siddiqui is the Director of Large Molecule & Biomarkers Bioanalysis at KCAS. He possess in-depth knowledge of regulatory guidelines including FDA, ICH, and EMEA combined with subject matter expertise in large molecule and vaccine early and late stage development. He has outstanding skills in ADA, PK, PD and biomarkers assay development, validation and bioanalysis according to GLP/GCP compliance in biotechnology and pharmaceutical companies. Prior to joining KCAS, he worked as a principal investigator to support large molecule and vaccine preclinical and clinical studies in Johnson & Johnson co, Merck and GSK. He has gained expertise in state-of-art bioanalytical techniques including MSD, Gyros, Luminex, ELISA, ELISPOT, Flow cytometry, Simoa, and RIA. Dr. Siddiqui received his PhD in immunology at Stockholm University and post-doctoral training in oncology at New York University and autoimmune disease at Stanford University. He has received several international recognitions for his outstanding research in immunology. He authored a book and many research articles in peer-reviewed journals.
Victor Green, BS
Victor has 26 years of experience working in bioanalytical laboratories; 11 of those years in Quality Assurance (QA). He spent five years as a QA specialist and has spent the last six years in QA management. He has been a Registered Quality Assurance Professional in GLPs since 2002. Since joining KCAS in 2006, he has played an important role in client interactions regarding KCAS’ quality as well as implementing quality improvement in practices, procedures and training. As Director of Quality Assurance, Green has been involved in multiple FDA regulatory inspections and client audits. He supervises quality staff auditing activities for projects and clients, which involves resolving quality issues, notifying senior management of issues related to quality and providing status updates for GLP studies. Prior to joining KCAS, Green had 16 years experience as a chemist in bioanalytical laboratories for Marion Merrel Dow, Hoechst Marion Roussel and Quintiles.